Mostrando 2 resultados de: 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors
ArticleAbstract: Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive aPalabras claves:Autores:Adrián LLerena, Bishop J.R., Caudle K.E., Chiulli D.L., Gaedigk A., Graham R.L., Hicks J.K., Ji Y., Klein T.E., Leckband S.G., Leeder J.S., Muller D.J., Sangkuhl K., Scott S.A., Skaar T.C., Stingl J.C.Fuentes:scopusCYP450 genotype and pharmacogenetic association studies: A critical appraisal
ReviewAbstract: Despite strong pharmacological support, association studies using genotype-pbkp_redicted phenotype aPalabras claves:drug metabolizing enzymes, ethnicity, Genotype, pharmacogenetic association studies, pharmacogenetics, phenoconversion, Phenotype, substrate-selectivity, Therapeutic drug monitoringAutores:Adrián LLerena, Eichelbaum M., Gaedigk A., Shah R.R., Smith R.L., Stingl J.C.Fuentes:scopus